Momentum in MDS: Making Progress and Shaping a Better Future

December 5, 2025

The MDSF ASH 2025 Symposium will focus on several topics within the interests of the general hematologic society in general, and the MDS community in particular, as well as the general public, including patients and their caregivers. A special emphasis will be given to topics relevant especially in 2025.

Target Audience

This activity is designed for an audience of nurses, pharmacists, physicians, and physician associates.

Learning Objectives

  • Identify and apply updated international guidelines for the diagnosis and treatment of Myelodysplastic Syndromes (MDS), enhancing global clinical practice.
  • Evaluate the current and future role of morphology in MDS, and distinguish when traditional techniques are necessary versus when modern technologies may provide suitable alternatives.
  • Analyze emerging evidence on germline predisposition in MDS and determine appropriate conditions for proactive versus conservative management strategies.
  • Explain the general process of drug development, with a focus on MDS, and interpret clinical trial data to inform real-world treatment decisions.
  • Integrate scientific findings with patient perspectives by discussing real-life challenges, thereby enhancing patient-centered care in MDS management.

Commercial Support
This activity is supported from an independent medical education grant from Agios Pharmaceuticals, Inc., Bristol Myers Squibb, Geron Corporation, Rigel Pharmaceuticals, Inc., and Taiho Oncology, Inc.

Course summary
Available credit: 
  • 3.00 AAPA Category 1 CME

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 3.00 ACPE Pharmacist

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 3.00 contact hours.

  • 3.00 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 3.00 ANCC Contact Hours

    Credit being awarded: 3.00 ANCC contact hours

  • 3.00 Attendance

    Credits: 3.00

Course opens: 
09/12/2025
Course expires: 
06/30/2026
Event starts: 
12/05/2025 - 7:00am EST
Event ends: 
12/05/2025 - 10:00pm EST
Cost:
$0.00
Add to calendar: 
Rating: 
0
Orlando, FL
United States

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product 
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer 
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.

Committee Member, Planner, Staff(s)

Michele Bielarski, RN

has no relevant financial relationships to disclose at this time.

Dorothy Duffy, RPh

has no relevant financial relationships to disclose at this time.

Lea Harrison

has no relevant financial relationships to disclose at this time.

Rebecca Lakofsky, BSN, RN

has no relevant financial relationships to disclose at this time.

Stephen Nimer, MD

has no relevant financial relationships to disclose at this time.

Valeria Santini, MD

has a financial relationship (Advisor) with AbbVie;.
has a financial relationship (Advisor) with Ascentage;.
has a financial relationship (Advisor) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Advisor) with Curis;.
has a financial relationship (Advisor) with Geron;.
has a financial relationship (Advisor) with GlaxoSmithKline;.
has a financial relationship (Advisor) with Jazz;.
has a financial relationship (Advisor) with Keros;.
has a financial relationship (Advisor) with Novartis;.
has a financial relationship (Advisor) with Menarini;.
has a financial relationship (Advisor) with Servier;.
has a financial relationship (Advisor) with CTI;.
has a financial relationship (Advisor) with Syros;.
has a financial relationship (Consultant) with AbbVie;.
has a financial relationship (Consultant) with Ascentage;.
has a financial relationship (Consultant) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Consultant) with Curis;.
has a financial relationship (Consultant) with Geron;.
has a financial relationship (Consultant) with GlaxoSmithKline;.
has a financial relationship (Consultant) with Jazz;.
has a financial relationship (Consultant) with Keros;.
has a financial relationship (Consultant) with Novartis;.
has a financial relationship (Consultant) with Menarini;.
has a financial relationship (Consultant) with Servier;.
has a financial relationship (Consultant) with CTI;.
has a financial relationship (Consultant) with Syros;.
has a financial relationship (Speaker) with AbbVie;.
has a financial relationship (Speaker) with Ascentage;.
has a financial relationship (Speaker) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Speaker) with Curis;.
has a financial relationship (Speaker) with Geron;.
has a financial relationship (Speaker) with GlaxoSmithKline;.
has a financial relationship (Speaker) with Jazz;.
has a financial relationship (Speaker) with Keros;.
has a financial relationship (Speaker) with Novartis;.
has a financial relationship (Speaker) with Menarini;.
has a financial relationship (Speaker) with Servier;.
has a financial relationship (Speaker) with CTI;.
has a financial relationship (Speaker) with Syros;.
has a financial relationship (Independent contractor (including contracted research)) with Bristol Myers Squibb/Celgene;.

Peggy Ann Torney

has no relevant financial relationships to disclose at this time.
Reviewer(s)

Michele Bielarski, RN

has no relevant financial relationships to disclose at this time.

Dorothy Duffy, RPh

has no relevant financial relationships to disclose at this time.

Rebecca Lakofsky, BSN, RN

has no relevant financial relationships to disclose at this time.
Speaker, Instructor, Faculty(s)

Rafael Bejar, MD, PhD

has a financial relationship (Consultant) with Ipsen;.
has a financial relationship (Consultant) with Keros;.
has a financial relationship (Consultant) with NeoGenomics;.
has a financial relationship (Advisor) with Servier;.
has a financial relationship (Advisor) with Geron;.
has a financial relationship (Royalties or patent beneficiary) with Genoptix;.
has a financial relationship (Speaker) with BMS;.

Rena Buckstein, MD, FRCPC

has a financial relationship (Advisor) with BMS;.
has a financial relationship (Researcher) with bms;.
has a financial relationship (Consultant) with BMS;.
has a financial relationship (Consultant) with TAIHO;.
has a financial relationship (Researcher) with TAIHO;.
has a financial relationship (Advisor) with TAKEDA;.

Carmelo Gurnari, MD PhD

has a financial relationship (Advisor) with Sobi;.
has a financial relationship (Advisor) with Novartis;.
has a financial relationship (Consultant) with Genesis Therapeutics;.

Robert Hasserjian, MD

has a financial relationship (Consultant) with Bluebird Bio.;.
has a financial relationship (Consultant) with Servier Pharm.;.

Moshe Mittelman, MD, PhD

has a financial relationship (Consultant) with CannaLean/Talent;.
has a financial relationship (Consultant) with Fibrogen;.
has a financial relationship (Consultant) with Agios;.

Stephen Nimer, MD

has no relevant financial relationships to disclose at this time.

Valeria Santini, MD

has a financial relationship (Advisor) with AbbVie;.
has a financial relationship (Advisor) with Ascentage;.
has a financial relationship (Advisor) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Advisor) with Curis;.
has a financial relationship (Advisor) with Geron;.
has a financial relationship (Advisor) with GlaxoSmithKline;.
has a financial relationship (Advisor) with Jazz;.
has a financial relationship (Advisor) with Keros;.
has a financial relationship (Advisor) with Novartis;.
has a financial relationship (Advisor) with Menarini;.
has a financial relationship (Advisor) with Servier;.
has a financial relationship (Advisor) with CTI;.
has a financial relationship (Advisor) with Syros;.
has a financial relationship (Consultant) with AbbVie;.
has a financial relationship (Consultant) with Ascentage;.
has a financial relationship (Consultant) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Consultant) with Curis;.
has a financial relationship (Consultant) with Geron;.
has a financial relationship (Consultant) with GlaxoSmithKline;.
has a financial relationship (Consultant) with Jazz;.
has a financial relationship (Consultant) with Keros;.
has a financial relationship (Consultant) with Novartis;.
has a financial relationship (Consultant) with Menarini;.
has a financial relationship (Consultant) with Servier;.
has a financial relationship (Consultant) with CTI;.
has a financial relationship (Consultant) with Syros;.
has a financial relationship (Speaker) with AbbVie;.
has a financial relationship (Speaker) with Ascentage;.
has a financial relationship (Speaker) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Speaker) with Curis;.
has a financial relationship (Speaker) with Geron;.
has a financial relationship (Speaker) with GlaxoSmithKline;.
has a financial relationship (Speaker) with Jazz;.
has a financial relationship (Speaker) with Keros;.
has a financial relationship (Speaker) with Novartis;.
has a financial relationship (Speaker) with Menarini;.
has a financial relationship (Speaker) with Servier;.
has a financial relationship (Speaker) with CTI;.
has a financial relationship (Speaker) with Syros;.
has a financial relationship (Independent contractor (including contracted research)) with Bristol Myers Squibb/Celgene;.

David Steensma, MD

has a financial relationship (Employee) with Ajax Therapeutics;.

Arjan van de Loosdrecht, MD, PhD

has no relevant financial relationships to disclose at this time.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and MDS Foundation. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 3 contact hours.

Nursing
Credit being awarded: 3 ANCC contact hours

Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 3.00 AAPA Category 1 CME

    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

  • 3.00 ACPE Pharmacist

    Pharmacists
    AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 3.00 contact hours.

  • 3.00 AMA PRA Category 1 Credit™

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 3.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 3.00 ANCC Contact Hours

    Credit being awarded: 3.00 ANCC contact hours

  • 3.00 Attendance

    Credits: 3.00

Price

Cost:
$0.00
Please login or register to take this course.

There is no fee to participate in this activity. Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and upon completion of an online evaluation/claimed credit form. You must participate in the entire activity to receive credit. If you have questions about this /CE activity, please contact AKH Inc. at [email protected]. Please claim your credit by 1/6/2026.